These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 23070004)

  • 21. Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseases.
    Srimatkandada P; Loomis R; Carbone R; Srimatkandada S; Lacy J
    Eur J Haematol; 2008 May; 80(5):407-18. PubMed ID: 18221384
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel.
    Wang Z; Goulet R; Stanton KJ; Sadaria M; Nakshatri H
    Anticancer Res; 2005; 25(3c):2367-79. PubMed ID: 16080463
    [TBL] [Abstract][Full Text] [Related]  

  • 23. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors.
    Ashkenazi A; Fairbrother WJ; Leverson JD; Souers AJ
    Nat Rev Drug Discov; 2017 Apr; 16(4):273-284. PubMed ID: 28209992
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Directly targeting the mitochondrial pathway of apoptosis for cancer therapy using BH3 mimetics - recent successes, current challenges and future promise.
    Sarosiek KA; Letai A
    FEBS J; 2016 Oct; 283(19):3523-3533. PubMed ID: 26996748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance.
    Shahar N; Larisch S
    Drug Resist Updat; 2020 Sep; 52():100712. PubMed ID: 32599435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Splice variants in apoptotic pathway.
    Miura K; Fujibuchi W; Unno M
    Exp Oncol; 2012 Oct; 34(3):212-7. PubMed ID: 23070006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BCL-2 protein family: attractive targets for cancer therapy.
    Kaloni D; Diepstraten ST; Strasser A; Kelly GL
    Apoptosis; 2023 Feb; 28(1-2):20-38. PubMed ID: 36342579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological inhibition of the Bcl-2 family of apoptosis regulators as cancer therapy.
    Richardson A; Kaye SB
    Curr Mol Pharmacol; 2008 Nov; 1(3):244-54. PubMed ID: 20021437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of dimeric modulators for anti-apoptotic Bcl-2 proteins.
    Wang L; Kong F; Kokoski CL; Andrews DW; Xing C
    Bioorg Med Chem Lett; 2008 Jan; 18(1):236-40. PubMed ID: 18023349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The BCL-2 protein family, BH3-mimetics and cancer therapy.
    Delbridge AR; Strasser A
    Cell Death Differ; 2015 Jul; 22(7):1071-80. PubMed ID: 25952548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting Bcl-2 for cancer therapy.
    Zhang L; Lu Z; Zhao X
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188569. PubMed ID: 34015412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting anti-apoptotic BCL-2 family proteins for cancer treatment.
    Zhang X; Liu X; Zhou D; Zheng G
    Future Med Chem; 2020 Apr; 12(7):563-565. PubMed ID: 32083493
    [No Abstract]   [Full Text] [Related]  

  • 33. Targeting BCL-2 regulated apoptosis in cancer.
    Campbell KJ; Tait SWG
    Open Biol; 2018 May; 8(5):. PubMed ID: 29769323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The mystery of BCL2 family: Bcl-2 proteins and apoptosis: an update.
    Siddiqui WA; Ahad A; Ahsan H
    Arch Toxicol; 2015 Mar; 89(3):289-317. PubMed ID: 25618543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Co-crystallization with conformation-specific designed ankyrin repeat proteins explains the conformational flexibility of BCL-W.
    Schilling J; Schöppe J; Sauer E; Plückthun A
    J Mol Biol; 2014 Jun; 426(12):2346-62. PubMed ID: 24747052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics.
    Hata AN; Engelman JA; Faber AC
    Cancer Discov; 2015 May; 5(5):475-87. PubMed ID: 25895919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting PUMA/Bcl-xL interaction by new specific compounds to unleash apoptotic process in cancer cells.
    Ramana Murthy AV; Narendar V; Kumar NS; Aparna P; Durga Bhavani AK; Gautier F; Barillé-Nion S; Juin P; Mosset P; Grée R; Levoin N
    Eur J Med Chem; 2019 Jan; 162():334-347. PubMed ID: 30453244
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation of neuronal cell death and neurodegeneration by members of the Bcl-2 family: therapeutic implications.
    Shacka JJ; Roth KA
    Curr Drug Targets CNS Neurol Disord; 2005 Feb; 4(1):25-39. PubMed ID: 15723611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic targeting of Bcl-2 family for treatment of B-cell malignancies.
    Huang J; Fairbrother W; Reed JC
    Expert Rev Hematol; 2015 Jun; 8(3):283-97. PubMed ID: 25912824
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer.
    D'Aguanno S; Del Bufalo D
    Cells; 2020 May; 9(5):. PubMed ID: 32455818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.